In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Arcadia Biosciences (RKDA – Research Report), with a price target of $6.00. The company's shares closed last Friday at $1.04, close to its 52-week low of $0.99. According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Currently, the analyst consensus on Arcadia Biosciences is a Moderate Buy with an average price target of $5.25.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-arcadia-biosciences-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral